Prime Research

Latest Research

February 2022 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to manage new drugs. Our clinical and trade relations teams keep a keen…

Read More

Drug Pipeline Quarterly Update: December 2021

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA…

Read More

Biosimilar strategy for rituximab using MedDrive™

Rituxan® (rituximab) from Genentech was first approved by the FDA in 1997 for treatment of non-Hodgkin’s lymphoma. It went on to receive FDA approval for…

Read More
Select a Research Type
Drug pipeline updates
Prime analysis
Scientific presentations
Loading …